Market Place
Sourcing Support
Curevo Raises $110M for Amezosvatein Shingles Vaccine
17 Mar 2025 //
GLOBENEWSWIRE
Curevo Shares Positive Ph 2 Data For Amezosvatein Shingles Vaccine
12 Jan 2025 //
GLOBENEWSWIRE
Curevo Vaccine to present at 43rd Annual J.P. Morgan Conference
08 Jan 2025 //
GLOBENEWSWIRE
Curevo Presents Positive Shingles Vaccine Outcomes Data
31 Oct 2024 //
GLOBENEWSWIRE
Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week
16 Oct 2024 //
GLOBENEWSWIRE
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer
08 Apr 2024 //
GLOBENEWSWIRE
Curevo’s shingles vaccine equals Shingrix in ph. 2 head-to-head
08 Jan 2024 //
FIERCE BIOTECH
Curevo Announces Positive Topline Results from Phase 2 Trial of Amezosvatein
07 Jan 2024 //
GLOBENEWSWIRE
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
GLOBENEWSWIRE
Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer
11 Apr 2023 //
GLOBENEWSWIRE
Curevo Vaccine Announces $26 Million Series A1 Financing
16 Nov 2022 //
BUSINESSWIRE
Curevo concludes subject enrolment in Phase IIb shingles vaccine trial
16 Sep 2022 //
CLINICALTRIALSARENA
Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101
15 Sep 2022 //
PRNEWSWIRE
Curevo will go head-to-head against GSK`s Shingrix with $60M
03 Feb 2022 //
FIERCEBIOTECH
Curevo Vaccine Announces the Approval to Conduct a Phase 1b Clinical Trial
30 Mar 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.